Vertex Pharmaceuticals Incorporated

Total Valuation

Vertex Pharmaceuticals Incorporated carries a market capitalization of 107.89B, placing it among publicly traded companies globally. Its enterprise value stands at 108.64B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Vertex Pharmaceuticals Incorporated currently has 254.16M shares outstanding.

Valuation Ratios

Vertex Pharmaceuticals Incorporated trades at a trailing price-to-earnings ratio of 26.25. The price-to-sales ratio is 9.32, and the price-to-book ratio stands at 7.80.

Enterprise Valuation

On an enterprise value basis, Vertex Pharmaceuticals Incorporated trades at an EV/EBITDA multiple of 22.27 and an EV/FCF ratio of 22.73. The EV/Sales ratio of 8.89 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 23.30 provides insight into valuation relative to core operating earnings.

Financial Position

Vertex Pharmaceuticals Incorporated maintains a current ratio of 3.02, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.26, indicating elevated leverage, while an interest coverage ratio of 473.73 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Vertex Pharmaceuticals Incorporated posts a return on equity of 34.92 and a return on invested capital of 19.83.

Taxes

Over the trailing twelve months, Vertex Pharmaceuticals Incorporated has paid 827.40M in income taxes, reflecting an effective tax rate of 16.02.

Stock Price Statistics

Vertex Pharmaceuticals Incorporated's stock has declined approximately -4.79081% over the past 52 weeks. The 50-day moving average sits at 437.70, while the 200-day moving average is 436.45.

Income Statement

Over the trailing twelve months, Vertex Pharmaceuticals Incorporated generated 12.22B in revenue and converted that into 4.34B in net income, yielding earnings per share of 16.87. EBITDA reached 4.88B, while operating income came in at 4.66B.

Balance Sheet

Vertex Pharmaceuticals Incorporated holds 7.25B in cash and equivalents against 1.99B in total debt, resulting in a net debt position of -5.49B. Total book value stands at 14.59B, with working capital of 7.85B providing operational flexibility.

Cash Flow

Vertex Pharmaceuticals Incorporated produced 4.24B in operating cash flow over the past twelve months. After subtracting -530.30M in capital expenditures, free cash flow totaled 3.71B - equivalent to 14.55 per share.

Margins

Vertex Pharmaceuticals Incorporated operates with a gross margin of 86.24, reflecting its pricing power and cost economics. The operating margin of 38.16 and net profit margin of 35.51 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Vertex Pharmaceuticals Incorporated's most recent stock split took place on August 24, 2000 with a 1:2 split ratio.

Scores

Vertex Pharmaceuticals Incorporated posts an Altman Z-Score of 11.90, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.